Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 11/20 | 0.42 |
| ▸ | ANPEP | P15144 | 2/20 | 0.39 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1861190 | 0.79 | L3MBTL1 (0.46) | ANPEPERAP2L3MBTL1TDP1HPGD | |
| SCHEMBL1860829 | 0.71 | HPGD (0.42) | ANPEPL3MBTL1TDP1HPGD | |
| SCHEMBL10890023 | 0.70 | EPHX1 (0.45) | EPHX1ANPEPERAP2TDP1HPGD | |
| SCHEMBL1859118 | 0.66 | EPHX2 (0.46) | EPHX1ANPEPERAP2TDP1HPGD | |
| SCHEMBL1861530 | 0.66 | EPHX2 (0.46) | EPHX1ANPEPERAP2TDP1HPGD | |
| SCHEMBL10871667 | 0.65 | EPHX2 (0.45) | EPHX1ANPEPERAP2TDP1HPGD | |
| SCHEMBL3289204 | 0.64 | DPP4 (0.49) | EPHX1ANPEPERAP2TDP1TAAR1 | |
| SCHEMBL10716724 | 0.64 | DPP4 (0.49) | EPHX1ANPEPERAP2TDP1TAAR1 | |
| SCHEMBL1529636 | 0.64 | EPHX1 (0.46) | EPHX1ANPEPHPGDTAAR1 | |
| SCHEMBL11998010 | 0.64 | SLC15A1 (0.44) | EPHX1ANPEPERAP2TDP1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105506-A1 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105506-A1 | Diaminoalkane aspartic protease inhibitors | DNPEP, PEPD, ACE | EPHX1 1377/4885ANPEP 12/4885ERAP2 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.